Barinthus Biotherapeutics plc
BRNS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.00 | -0.15 | 0.08 |
| FCF Yield | -62.66% | -39.77% | -23.50% | -8.16% |
| EV / EBITDA | 0.92 | -0.18 | -15.32 | -4.31 |
| Quality | ||||
| ROIC | 0.79% | -39.54% | -9.79% | -16.72% |
| Gross Margin | 100.00% | -579.18% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.47 | 0.69 | -2.71 | 0.64 |
| Growth | ||||
| Revenue 3-Year CAGR | -30.56% | 44.11% | 110.09% | -66.04% |
| Free Cash Flow Growth | 47.05% | -173.90% | 39.02% | -197.93% |
| Safety | ||||
| Net Debt / EBITDA | 1.78 | 1.82 | -28.98 | 4.32 |
| Interest Coverage | 22.19 | -2,996.93 | -212.68 | -16.95 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 161.31 | 3,613.14 | 99.66 | 9,675.22 |